Surgery, Gastroenterology and Oncology
Official journal of the International Association of Surgeons, Gastroenterologists and Oncologists
|
|
Bariatric Surgery is Safe During COVID-19 Pandemic
Background: The Coronavirus Disease 2019 (COVID-19) pandemic has massively affected bariatric surgical practises across the world. Aim: This report aims to show the effects of the pandemic on bariatric practices in the UK during the early phase of the pandemic.
Methods: Bariatric surgeons in United Kingdom (UK) were contacted; seven bariatric units and 20 collaborators agreed to participate in this project. The data includes patientsâ?? demographics, type and number of operations, bariatric endoscopic procedures, management of complications, emergency and revisional bariatric surgery. Statistical analysis was used to assess the differences among the categories and to compare the data to the 6th report outcomes provided by British Obesity and the Metabolic Surgery Society 2017â?"2018 (NBSR). Further analysis of mortality between pre pandemic era and June 2020-June 2021 was performed.
Results: A total of 430 bariatric procedures were conducted from 1 January 2020 to 31 March 2020 in seven hospitals in UK. The mean age of the patients was 43.3 years. The mean body mass index was 46.75 kg m2. 314 (73%) of the patients were women and 116 (27%) were men. The following procedures were performed: 118 (27.4%) Laparoscopic Sleeve Gastrectomy (LSG), 114 (26.5%) One Anastomosis Gastric Bypass (OAGB), 76 (17.6%) Roux En-Y Gastric Bypass (RYGB), 61 (14.18%) Gastric Balloon and 15 (3.5%) Adjustable Gastric Band. 176 bariatric endoscopy procedures were performed for different indications. 26 (6.04%) revisional surgeries and 20 (4.6%) emergency bariatric surgeries were performed. 24 (5.58%) patients had Grade Iâ?"IV Clavienâ?"Dindo complications. No mortality was reported. There was a significant difference in the number of operations for each of LSG, RYGB and OAGB in these seven hospitals compared to the data provided by the British Obesity and Metabolic Surgery Society (BOMSS) 2017â?"2018 .Only one patient was diagnosed with COVID-19, who was successfully treated and discharged home. Only one mortality was reported during June 2020 untill June 2021.There was no significant difference in moratlity between pre and post pandemic, p>0.5.
Conclusions: This data reveals safe bariatric practices during the early phase of COVID-19.
Full Text Sources:
Abstract:
Views: 2183
Methods: Bariatric surgeons in United Kingdom (UK) were contacted; seven bariatric units and 20 collaborators agreed to participate in this project. The data includes patientsâ?? demographics, type and number of operations, bariatric endoscopic procedures, management of complications, emergency and revisional bariatric surgery. Statistical analysis was used to assess the differences among the categories and to compare the data to the 6th report outcomes provided by British Obesity and the Metabolic Surgery Society 2017â?"2018 (NBSR). Further analysis of mortality between pre pandemic era and June 2020-June 2021 was performed.
Results: A total of 430 bariatric procedures were conducted from 1 January 2020 to 31 March 2020 in seven hospitals in UK. The mean age of the patients was 43.3 years. The mean body mass index was 46.75 kg m2. 314 (73%) of the patients were women and 116 (27%) were men. The following procedures were performed: 118 (27.4%) Laparoscopic Sleeve Gastrectomy (LSG), 114 (26.5%) One Anastomosis Gastric Bypass (OAGB), 76 (17.6%) Roux En-Y Gastric Bypass (RYGB), 61 (14.18%) Gastric Balloon and 15 (3.5%) Adjustable Gastric Band. 176 bariatric endoscopy procedures were performed for different indications. 26 (6.04%) revisional surgeries and 20 (4.6%) emergency bariatric surgeries were performed. 24 (5.58%) patients had Grade Iâ?"IV Clavienâ?"Dindo complications. No mortality was reported. There was a significant difference in the number of operations for each of LSG, RYGB and OAGB in these seven hospitals compared to the data provided by the British Obesity and Metabolic Surgery Society (BOMSS) 2017â?"2018 .Only one patient was diagnosed with COVID-19, who was successfully treated and discharged home. Only one mortality was reported during June 2020 untill June 2021.There was no significant difference in moratlity between pre and post pandemic, p>0.5.
Conclusions: This data reveals safe bariatric practices during the early phase of COVID-19.
Full Text Sources:
Abstract:
Views: 2183
Watch Video Articles
For Authors
Journal Subscriptions
Current Issue
Dec 2025
Supplements
Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
e-ISSN: 2601 - 1700 (online)
ISSN-L: 2559 - 723X
Journal Abbreviation: Surg. Gastroenterol. Oncol.
Surgery, Gastroenterology and Oncology (SGO) is indexed in:
- SCOPUS
- EBSCO
- DOI/Crossref
- Google Scholar
- SCImago
- Harvard Library
- Open Academic Journals Index (OAJI)
Open Access Statement
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.
Journal Metrics
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2
IASGO Society News
Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.